Status:
NOT_YET_RECRUITING
Advancing Lung Cancer Screening: Artificial Intelligence, Multimodal Imaging and Cutting-Edge Technologies for Early Detection and Characterization
Lead Sponsor:
IRCCS San Raffaele
Collaborating Sponsors:
Fondazione Policlinico Universitario Campus Bio-Medico
University of Calabria
Conditions:
Lung Cancer Screening
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Currently available screening programmes for lung cancer are limited by many challenges including low diagnostic accuracy, radiation exposure and high costs. New technologies in PET/CT scanners can al...
Detailed Description
Assessment of the potential added value of low dose \[18F\]FDG PET/CT in the early detection of lung cancer in the screening work-up of the high-risk population. The target population (cohort 1) for t...
Eligibility Criteria
Inclusion
- Age \> 50 years
- PLCOm2012 risk prediction \> 4%
- Be willing to adhere to the study intervention through \[18F\]FDG PET/CT or LDCT imaging
- Signed written informed consent form
Exclusion
- Blood glucose levels \>200 mg/dl,
- Ongoing pregnancy and breastfeeding
- Unwillingness to participate,
- Previous diagnosis of lung cancer,
- Previous CT scan within the last 24 months
- Concomitant severe clinical conditions and any condition that preclude the feasibility of the study
Key Trial Info
Start Date :
October 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT06531343
Start Date
October 30 2024
End Date
August 30 2026
Last Update
October 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs San Raffaele
Milan, Italy